Research Article

High-Throughput Analysis of the T Cell Receptor Beta Chain Repertoire in PBMCs from Chronic Hepatitis B Patients with HBeAg Seroconversion

Yachao Qu,1 Yong Huang,2 Di Liu,3 Yinuo Huang,1 Zhiyi Zhang,2 Zhiqiang Mi,2 Xiaoping An,2 Yigang Tong,2 and Jun Lu1

1Hepatology and Cancer Biotherapy Ward, Beijing You'an Hospital, Capital Medical University, Beijing, China
2State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China
3Network Information Center, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China

Correspondence should be addressed to Yigang Tong; tong.yigang@gmail.com and Jun Lu; lujun98@ccmu.edu.cn

Received 27 March 2016; Revised 4 July 2016; Accepted 21 July 2016

1. Introduction

According to the World Health Organization, two billion people worldwide are infected with hepatitis B virus (HBV), and 350 million people are chronically infected. Approximately one million people die each year due to HBV infection, which leads to cirrhosis, liver failure, and/or hepatocellular carcinoma [1]. Therefore, understanding the pathogenesis of chronic hepatitis B (CHB) is of great importance. The natural history of HBV is influenced by the host, virus, and microenvironment [2]. Circumstantial evidence suggests that HBV does not directly lead to hepatocyte necrosis. Hepatocyte injury caused by HBV is believed to be mediated by the cellular immune response against the virus [3]. This response is relatively strong in acute, self-limited HBV infection. However, circulating HBV-specific T cells are rarely detected in CHB [4].

A healthy adult has approximately $2.5 \times 10^7$ different polyclonal T cells, each of which expresses a particular T cell receptor (TCR) [5]. TCR is a heterodimer consisting of $\alpha$ and $\beta$ protein chains that determine T lymphocyte specificity [6]. TCR diversity is generated by the somatic recombination of the V, D (for TCR$\beta$ only), and J gene segments [7]. In the process of T cell maturation, allelic exclusion ensures that only one $\beta$ chain protein is expressed in T cells [8]. Therefore, TCR$\beta$ chains can be used as molecular fingerprints to identify T cell clones. Human TCR$\beta$ includes 48 different functional V, 13 J, and 2 D gene segments in addition to 10 J and 18 V pseudogenes, which can be rearranged [9]. A number of techniques have been applied to analyze the TCR repertoire [10]; for example, flow cytometry is commonly employed; however, this method is limited by anti-TRB antibody specificity [11]. Gene melting spectral pattern (GMSP) assay, which is used to analyze the TCR gene
family, is widely used [12]. Because this technique requires a large number of PCR reactions including primers for all possible V and J genes, its application is limited. Delayed data availability and the inability to detect variations in TCRβ chain sequences are further drawbacks. More powerful diagnostic tools are therefore needed to accurately assess TCR diversity that can be used to monitor immune reconstitution, therapeutic responses, and disease status and to identify the T cell clonotypes in different diseases.

In recent years, next-generation sequencing (NGS), a fast and accurate new method, has been applied in various fields of medicine, with high coverage and massively parallel DNA sequence identification [13, 14]. In this study, we collected peripheral blood mononuclear cells (PBMCs) from CHB patients undergoing treatment. Using NGS, we compared the TCRβ repertoire before and after HBeAg seroconversion in these patients and determined the pathogenesis of CHB during treatment. This study has generated new ideas for the development of effective individual treatment strategies and research technology platforms.

The purpose of our study was to elucidate the molecular portrait of TCRβ chains in PBMCs from CHB patients and to reveal the role of cell-mediated immunity in the pathogenesis of chronic HBV infection to facilitate the development of individualized treatment.

2. Materials and Methods

2.1. Subjects. Between April 2012 and July 2013, 18 patients with hepatitis B surface antigen (HBsAg) that tested positive for at least 6 months were enrolled in our study. The subjects were selected at the Beijing You’an Hospital, affiliated with Capital Medical University. Individuals with hepatitis C or D or human immunodeficiency (HIV) virus or autoimmune disease and other malignancies were excluded. This study was performed in accordance with the principles of the Declaration of Helsinki. All patients provided informed consent before the initiation of the study. Each patient was treated orally with 0.5 mg entecavir (Bristol-Myers Squibb, USA) before the initiation of the study. Each patient was treated once a day for 48 weeks and injection of 1.6 mg thymosin α1 (Life, New York, USA), which contains 10% MDSO and 20% bovine serum, and then placed in a Cryo I' Freezing Container (Nalgene, USA) for storage at −80 °C until use in the experiments.

2.4. Total RNA Isolation and cDNA Synthesis. Total RNA was extracted from PBMCs using RNA (RNaseasy kit) according to the manufacturer's instructions, and cDNA synthesis was performed immediately with cDNA (Superscript II).

2.5. PCR cDNA Amplification and TCRβ Chain Sequencing. PCR was performed with a Thermal Cycler PCR System 2720 (Gene Company Limited). One round of PCR was carried out to amplify cDNA. Each 50 µL PCR reaction contained 2 µL cDNA, 12 µL ddH₂O, 25 µL Premix Ex Taq (TaKaRa), 200 nM of the specific primer CP1 (GCACCTCCTTCCCCATTCCAC, which targets C region genes [15]), and 2 µL of the degenerate primer VPI (GCCITKTIYTGGTAYMGACA, which targets the V region and covers 42 Vβ chains [15]). The PCR program was as follows: one cycle at 94 °C for 10 min, followed by 40 cycles at 94 °C for 30 s, 50 °C for 30 s, and 72 °C for 30 s, with a final 10 min extension at 72 °C and a 4 °C hold. Ten milliliters of each PCR product was run on a 2% agarose gel (150 V, 45 min), and products of approximately 400 bp were excised and purified using a Gel Extraction Kit (Qiagen, Hilden, Germany). The library was prepared according to the Ion Torrent sequencing manufacturer's instructions. The PGM sensed the H+ signal as sequencing-by-syntheses progressed [16].

2.6. Analysis of TCR Diversity. A Blast+ [17] search was carried out for the alignment-based identification of individual amplicons against TCRβ chain germ line genes (63 TRBV, 2 TRBD, and 14 TRBJ), which were derived from IMGT/GENE-DB database (http://imgt.cines.org/). A homemade Perl script was used to analyze the Blast results and quantify the TRBV and TRBJ gene pairings, including the TRBV-only and TRBJ-only amplicons.

3. Results

3.1. Clinical Outcomes. After antiviral treatment with entecavir and thymosin α1 for 48 weeks, 98% (17/18) of the patients had no detectable serum HBV DNA, the serum ALT level returned to normal, and 22.2% (4/18) of the patients achieved HBeAg seroconversion. No patient had undergone HBsAg seroconversion by week 48 of treatment. PBMCs were collected from the 4 patients before and after HBeAg seroconversion for TCR sequencing, and their clinical characteristics are summarized in Table 1.

Sequencing Data. The total numbers of sequencing reads for the 4 paired samples ranged from 370,210 to 685,596, with an average length of approximately 230 bp (Table 2). The average length may have been smaller than the library length because the PGM prevented some of the PCR amplicons from being fully sequenced. The ratio of Q20 (quality score of ≥20) bases to total bases sequenced ranged from 83.2% to 86.2%, indicating a high level of sequencing quality.

3.2. Biased Vβ and Jβ Gene Segments within TCRs. Among the productively rearranged clones from the PBMCs of the
patients, 30 V\(\beta\) gene segments and 14 J\(\beta\) gene segments were identified. The serial results of relative TCRV\(\beta\) and J\(\beta\) expression in the four patients (P1–P4) before and after HBeAg seroconversion are shown in Figure 1.

The gene fragments, which initially accounted for more than 5\%, were defined as the advantage segments. The expression levels of the V\(\beta\) genes were diverse. V\(\beta 12-4\) was the most common segment detected in the PBMCs of the four patients, with frequencies of 10.6\%, 9.2\%, 17.5\%, and 7.5\%, respectively. V\(\beta 28\) was also frequently found in the four patients at frequencies of 7.8\%, 6.7\%, 5.3\%, and 10.9\%, respectively. V\(\beta 12-5\) (10.6\%, 9.1\%, and 5.3\%), V\(\beta 19\) (12.3\%, 10.6\%, and 5.9\%), and V\(\beta 7-2\) (6.5\%, 5.6\%, and 9.8\%) were frequently observed in three of the patients, while other gene segments were detected in less than 5\% of the patients. Furthermore, we analyzed the differences between the two periods (before and after HBeAg seroconversion). A greater than 3\% fluctuation in the relative TCRV\(\beta\) gene expression ratio between the two stages was defined as a significant change. Several TCRV\(\beta\) families showed changes between the two time periods (P1: V\(\beta 12-4\) was upregulated and V\(\beta 12-5\), V\(\beta 19\), and V\(\beta 28\) were downregulated; P2: V\(\beta 12-5\), V\(\beta 19\), and V\(\beta 28\) were downregulated; P3: V\(\beta 10-3\) and V\(\beta 19\) were upregulated and V\(\beta 12-4\) and V\(\beta 23-1\) were downregulated; and P4: V\(\beta 28\) was upregulated and V\(\beta 27\) was downregulated). However, no common highly fluctuating TCRV\(\beta\) segment was found in the patients. Moreover, there was no correlation between the changes in TCRV\(\beta\) gene expression and the serum ALT or TBIL level.

With regard to J\(\beta\) gene expression, J\(\beta 2-1\) was the most abundant segment in the PBMCs of the four patients at frequencies of 5.8\%, 6.5\%, 11.3\%, and 7.3\%, respectively. J\(\beta 2-3\) (6.4\% and 17.3\%) and J\(\beta 2-7\) (8.8\% and 5.8\%) were frequently expressed in two of the patients, while other gene segments were detected in less than 5\% of cells from most of the patients. We also analyzed the changes in TCRJ\(\beta\) gene expression between the two periods. There were no significant differences between the two stages for the first two patients (P1 and P2). However, several J\(\beta\) segments were upregulated in the third patient (P3) (J\(\beta 1-1\), J\(\beta 1-2\), J\(\beta 1-5\), J\(\beta 2-1\), J\(\beta 2-3\), J\(\beta 2-5\), and J\(\beta 2-7\)), and J\(\beta 2-1\) was upregulated, while J\(\beta 2-3\) was downregulated, in the fourth patient (P4). Given that the third patient (P3) was the only female of the four subjects, it is possible that TCRJ\(\beta\) expression is affected by gender, further influencing the efficacy of therapy. Similarly, there was no correlation between the changes in TCRJ\(\beta\) gene expression and the serum ALT or TBIL level.

3.3. Restricted Changes in TCR\(\beta\)V\(\beta\)-J\(\beta\) Gene Pairing in the Four Patients. The sequencing reads showing similarity to certain V and J genes were defined as TCR\(\beta\)V\(\beta\)-J\(\beta\) gene pairings. TCR\(\beta\)V\(\beta\)-J\(\beta\) gene pairings were detected in the raw reads of four patients separately (both before and after treatment). Differences in the expression of each combination detected in the four patients are shown in Figure 2. Among the patients, there were several combinations that tended to be similarly differentially expressed following the shift from HBeAg positive to negative. For example, the combinations

### Table 1: Clinical characteristics of the enrolled patients.

| Patient Gender | Age (year) | ALT (IU/L) Before | ALT (IU/L) After | TBIL (μmol/L) Before | TBIL (μmol/L) After | HBV DNA (IU/mL) Before | HBV DNA (IU/mL) After | Test for hepatitis B Before | Test for hepatitis B After | HBsAg (IU/mL) Before | HBsAg (IU/mL) After |
|----------------|-----------|------------------|------------------|----------------------|------------------|----------------------|----------------------|--------------------------|--------------------------|----------------------|----------------------|
| P1 M           | 25        | 560.1            | 35.6             | 27.2                 | 12.2             | 1.64 × 10^4          | <100                 | 135+                     | 145+                     | 9273                 | 1968                 |
| P2 M           | 22        | 149.9            | 33               | 15.3                 | 12.5             | 6.26 × 10^4          | <100                 | 135+                     | 145+                     | 5005                 | 522.4                |
| P3 F           | 19        | 331.4            | 39.6             | 5.3                  | 9.9              | 2.60 × 10^4          | <100                 | 135+                     | 145+                     | 49394                | 227.6                |
| P4 M           | 39        | 60               | 37.3             | 14.3                 | 14.9             | 2.21 × 10^3          | <100                 | 135+                     | 145+                     | 9273                 | 1968                 |

M: male; F: female; ALT: alanine aminotransferase; TBIL: total bilirubin; 135+: HBsAg, HBeAg, and anti-HBc positive; 145+: HBsAg, anti-Hbe, and anti-HBc positive.

Normal values: ALT ≤ 40 IU/L; TBIL ≤ 21 μmol/L.

### Table 2: The number of raw sequencing reads and the rearranged TRBV\(\beta\)J\(\beta\) clones.

| Samples | Raw reads* | Average length (bp) | TRBV\(\beta\) gene pairing | TRBV-only gene | TRBJ-only gene | Nonhomologous |
|---------|------------|---------------------|-----------------------------|----------------|----------------|---------------|
| P1_pre  | 526,527    | 256                 | 122,007                     | 256,443        | 33,484         | 69,906        |
| P1_post | 526,527    | 224                 | 97,239                      | 263,323        | 60,92          | 87,755        |
| P2_pre  | 685,596    | 233                 | 119,794                     | 252,164        | 59,132         | 129,358       |
| P2_post | 685,596    | 228                 | 150,460                     | 332,818        | 83,253         | 106,459       |
| P3_pre  | 607,994    | 216                 | 169,465                     | 228,845        | 79,726         | 96,378        |
| P3_post | 607,994    | 236                 | 181,292                     | 231,489        | 73,901         | 82,747        |
| P4_pre  | 370,210    | 242                 | 101,415                     | 181,389        | 39,651         | 37,718        |
| P4_post | 370,210    | 232                 | 251,846                     | 37,457         | 35,291         | 27,889        |

*The reads used for analyses were adjusted from the raw sequencing data to guarantee that each patient has the same sample size in both pre- and posttreatments. TRBV\(\beta\): TCR beta chain variable gene; TRBJ\(\beta\): TCR beta chain junction gene.
4. Discussion

HBV infection is a major public health concern because it has significant impacts on human health. The different outcomes of HBV infection are determined by the immune status of the host. In acute self-limited HBV infection, the T cell response is strong, while it is relatively weak in patients with CHB [18]. Moreover, Dou et al. [19] have demonstrated that the population of HBcAg-activated T cells is altered during the course of CHB. The TCR\(\beta\) chain can reflect the status and role of T cells. There are also three complementarity-determining regions (CDR1, CDR2, and CDR3) in the TCR. Molecular structural analysis has revealed that CDR3 mainly recognizes MHC molecules bound to antigenic peptides [20, 21]. Hence, analysis of CDR3 can reveal changes in antigen-stimulated T cells [22, 23], the number of T cell clones, and T cell functioning [24, 25].

Analysis of TCR usage in patients can aid in the understanding of immune responses under a number of conditions during the course of a disease [26]. Sugyo et al. [27] monitored the TCR\(\beta\) chains of 4 healthy controls from 4 to 8 weeks, revealing that there was no significant change in the ratio. Many studies have confirmed that, in patients with viral infection or cancer, the frequency of antigen-specific TCRs differs [28, 29]. In our study, we observed several patients with the increased and/or decreased expression of TCR families, V7-2-01-J2-1, V12-4-J1-1, and V28-1-J1-5 were upregulated and V19-01-J2-3 was downregulated significantly following seroconversion.
Figure 2: The serial results of TCRβV_J gene pairings in the four patients (P1–P4) before and after HBeAg seroconversion. TCRβV_J gene pairings were detected in the raw reads of four patients separately (both before and after treatment). Among the patients, there were several combinations that tended to be similarly differentially expressed following the shift from HBeAg positive to negative.

which is consistent with previous studies suggesting that the T cell response to HBV employs diverse TCR families [12, 30]. The findings of this study are also in agreement with those of prior studies demonstrating that TCR families are biased [31]. These observations may be correlated with the different epitopes of HBV or to the different HLA phenotypes [31, 32].

Most patients with CHB are successfully treated with antiviral drugs. However, some require long-term therapy, and relapse is common. At present, HBV therapy is primarily based on the uses of nucleoside analogs and immunomodulating agents. The effects of these treatments are closely correlated with the rescue of T cell function, especially among HBV-specific T cells [4]. Furthermore, these treatments are often limited by drug resistance and side effects. Moreover, the response rate is low, and many patients subsequently relapse [33]. Hence, it is necessary to develop new interventions for HBV infection.

In recent years, many researchers have modified T cells with specific TCR genes to cure cancer and other diseases. Morgan et al. [34] have demonstrated that TCR gene-modified T cells could be used for treating melanoma. Xue et al. [35] engineered patients’ T cells to express WT1-TCR, which eliminates autologous leukemia progenitor cells, in an in vivo model. Their findings provide a strong basis for the planned WT1-TCR gene therapy trials of leukemia patients. Gehring et al. [36] used vector-mediated gene transfer to introduce HLA A2-restricted, HBV-specific TCRs into T cells of chronic HBV and HBV-related HCC patients and found that these genetically modified T cells could be used to reconstitute virus-specific T cell immunity in the chronic HBV patients and target tumors in the HBV-related HCC patients. In 2013, Koh et al. [37] performed electroporation of mRNA-encoding anti-HBV TCRs to explore a safer and more practical method for cell therapy of HCC that may also be employed to treat other HBV-related diseases. Krebs et al. [38] have demonstrated that T cells with a chimeric antigen receptor (CAR) specific for HBV envelope proteins localized to the livers of mice to reduce HBV replication cause only temporary damage. This immune therapy could be developed for CHB patients, regardless of their HLA type. Similar studies have also been conducted on acute hepatitis B and chronic severe hepatitis B patients [39, 40].

NGS was carried out to analyze TCR expression before and after HBeAg seroconversion in patients with CHB. High-throughput sequencing has been used to monitor the drug resistance of HBV [41]. Recently, Robins et al. [42] have studied TCR diversity in 2 healthy adults based on NGS and spectratyping, similarly showing the improved sensitivity of the former. Han et al. [43] have used high-throughput sequencing and suggested that comparison of the T cell repertoires of tissue and blood could be used to distinguish liver cancer patients from healthy adults and from hepatitis patients. Moreover, recent study of Huang et al. [44] has demonstrated that the genomic rearrangement of the V and J segments of TCRβ chain V area may be associated with the chronic progression of HBV and impact on treatment efficacy. We used this method to determine the exact length and sequence of CDR3 to identify TCRβ and Jβ genes.

A comparison of the two regions indicated that the TCRβ families Vβ12-4, Vβ12-5, Vβ19, Vβ28, Vβ7-2, Jβ2-1, Jβ2-3, and Jβ2-7 were more frequently expressed in the HBeAg-positive patients than the other TCR family members. These
results are consistent with those of other studies suggesting that TCR Vβ/β and Vβ12 are more abundant than other TCR Vβ genes in HBV-related infections [19, 40, 45] and other diseases [46].

Moreover, many Vβ-1β gene segment combinations were found to change with HBeAg status, and this activity may be specific to HBV antigens. However, it was difficult to identify the HBV peptides that these TCRs reacted to. Such biased usage of TCRs has also been reported by studies of multiple sclerosis, primary biliary cirrhosis, and autoimmune hepatitis [47–51]. Still, the identification of TCR families can help to elucidate the pathogenesis of and improve the treatment of hepatitis B.

In conclusion, the characteristics of TCRs in CHB patients are biased and involve multiple TCRβ families. The TCRβ V7-2-01-J2-1, V12-4-J1-1, V28-1-J1-5, and V19-01-J2-3 genes may contribute more to the emergence and maintenance of anti-HBe in CHB patients and may represent potential targets for a therapeutic vaccine for CHB. Crystal structure studies are needed in the future.

Competing Interests

The authors who took part in this study declare that they have nothing to disclose regarding funding or competing interests with respect to this manuscript.

Authors’ Contributions

Di Liu, Yigang Tong, and Jun Lu conceived and designed the experiments. Yachao Qu, Yong Huang, and Xiaoping An performed the experiments. Yong Huang, Zhiyi Zhang, Zhiqiang Mi, and Yachao Qu analyzed the data. Yachao Qu, Yong Huang, and Di Liu wrote the paper. Yachao Qu and Yong Huang contributed equally to this work.

Acknowledgments

The authors thank Xuli Bao and Lei Zhang for collecting samples. This study was supported by the “215” high-level health technology project (2011) and the “12th Five-Year” plan of major science and technology projects for major infectious disease prevention and control (2014ZX10002002-001-002).

References

[1] World Health Organization, “Hepatitis B,” Fact Sheet 204, WHO, Geneva, Switzerland, 2012.
[2] H. J. Yim and A. S.-F. Lok, “Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005,” Hepatology, vol. 43, no. 2, pp. S173–S181, 2006.
[3] D. R. Milich, “Immune response to hepatitis B virus proteins: relevance of the murine model,” Seminars in Liver Disease, vol. 11, no. 2, pp. 93–112, 1991.
[4] C. Boni, A. Penna, A. Bertolletti et al., “Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B,” Journal of Hepatology, vol. 39, no. 4, pp. 595–605, 2003.
[5] T. P. Arstila, A. Casrouge, V. Baron, J. Even, J. Kanellopoulos, and P. Kourilsky, “A direct estimate of the human αβ T cell receptor diversity,” Science, vol. 286, no. 5441, pp. 958–961, 1999.
[6] K. C. Garcia, L. Teyton, and I. A. Wilson, “Structural basis of T cell recognition,” Annual Review of Immunology, vol. 17, pp. 369–397, 1999.
[7] M. Kronenberg, G. Siu, L. E. Hood, and N. Shastri, “The molecular genetics of the T-cell antigen receptor and T-cell antigen recognition,” Annual Review of Immunology, vol. 4, pp. 529–591, 1986.
[8] B. L. Brady, N. C. Stein, and C. H. Bassing, “Antigen receptor allelic exclusion: an update and reappraisal,” The Journal of Immunology, vol. 185, no. 7, pp. 3801–3808, 2010.
[9] M.-P. Lefranc, “IMGT, the international ImMunoGeneTics database,” Nucleic Acids Research, vol. 31, no. 1, pp. 307–310, 2003.
[10] J. Even, A. Lim, I. Puisieux et al., “T-cell repertoires in healthy and diseased human tissues analysed by T-cell receptor β-chain CDR3 size determination: evidence for oligoclonal expansions in tumours and inflammatory diseases,” Research in Immunology, vol. 146, no. 2, pp. 65–80, 1995.
[11] J. P. Maciejewski, C. O’Keefe, L. Gondek, and R. Tiu, “Immune-mediated bone marrow failure syndromes of progenitor and stem cells: molecular analysis of cytotoxic T cell clones,” Folia Histochemica et Cytobiologica, vol. 45, no. 1, pp. 5–14, 2007.
[12] J. Yang, J. Chen, J. He et al., “Profiling the repertoire of T-cell receptor beta-chain variable genes in peripheral blood lymphocytes from subjects who have recovered from acute hepatitis B virus infection,” Cellular and Molecular Immunology, vol. 11, no. 4, pp. 332–342, 2014.
[13] R. A. Bull, F. Luciani, K. McElroy et al., “Sequential bottlenecks drive viral evolution in early acute hepatitis C virus infection,” PLoS Pathogens, vol. 7, no. 9, Article ID e1002243, 2011.
[14] F. Di Giannonardo, O. Zagordi, Y. Dupont et al., “Next-generation sequencing of HIV-1 RNA genomes: determination of error rates and minimizing artificial recombination,” PLoS ONE, vol. 8, no. 9, Article ID e74249, 2013.
[15] D. Zhou, R. Srivastava, V. Grummel, S. Cepok, H.-P. Hartung, and B. Hemmer, “High throughput analysis of TCR-β rearrangement and gene expression in single T cells,” Laboratory Investigation, vol. 86, no. 3, pp. 314–321, 2006.
[16] E. Pennisi, “Semiconductors inspire new sequencing technologies,” Science, vol. 327, no. 5970, p. 1890, 2010.
[17] C. Camacho, G. Coulouris, V. Avagyan et al., “BLAST+: architecture and applications,” BMC Bioinformatics, vol. 10, article 421, 2009.
[18] E. R. Sandalova, D. Laccabue, C. Boni et al., “Increased levels of arginase in patients with acute hepatitis B suppress antiviral T cells,” Gastroenterology, vol. 143, no. 1, pp. 78–87.e3, 2012.
[19] H.-Y. Dou, J.-C. Wu, W.-L. Peng et al., “Analysis of T cell receptor V(β) gene usage during the course of disease in patients with chronic hepatitis B,” Journal of Biomedical Science, vol. 5, no. 6, pp. 428–434, 1998.
[20] P. Marrack and J. Kappler, “Positive selection of thymocytes bearing αβ T cell receptors,” Current Opinion in Immunology, vol. 9, no. 2, pp. 250–255, 1997.
[21] P. Miqueu, M. Guillet, N. Degauche, J.-C. Doré, J.-P. Soulillou, and S. Brouard, “Statistical analysis of CDR3 length distribution for the assessment of T and B cell repertoire biases,” Molecular Immunology, vol. 44, no. 6, pp. 1057–1064, 2007.
[22] J.-W. Du, J.-Y. Gu, J. Liu et al., “TCR spectratyping revealed T lymphocytes associated with graft-versus-host disease after
allogeneic hematopoietic stem cell transplantation," *Leukemia and Lymphoma*, vol. 48, no. 8, pp. 1618–1627, 2007.

[23] M. Okajima, T. Wada, M. Nishida et al., “Analysis of T cell receptor Vß diversity in peripheral CD4+ and CD8+ T lymphocytes in patients with autoimmune thyroid diseases,” *Clinical and Experimental Immunology*, vol. 155, no. 2, pp. 166–172, 2009.

[24] A. Leimgruber, M. Ferber, M. Irving et al., “Tcrrep 3D: an automated in silico approach to study the structural properties of tcr repertoires,” *PloS ONE*, vol. 6, article e26301, 2011.

[25] D. K. Sethi, D. A. Schubert, A.-K. Anders et al., “A highly tilted binding mode by a self-reactive T cell receptor results in altered engagement of peptide and MHC,” *The Journal of Experimental Medicine*, vol. 208, no. 1, pp. 91–102, 2011.

[26] K. S. Seo, J. Y. Park, D. S. Terman, and G. A. Bohach, “A quantitative real time PCR method to analyze T cell receptor Vß subgroup expansion by staphylococcal superantigens,” *Journal of Translational Medicine*, vol. 8, article 2, 2010.

[27] S. Suguyo, K. Yuh, K. Nakamura et al., “An analysis of T cell antigen receptor variable β genes during the clinical course of patients with chronic hepatitis B,” *Journal of Gastroenterology and Hepatology*, vol. 14, no. 4, pp. 333–338, 1999.

[28] J. J. Miles, D. C. Douek, and D. A. Price, “Bias in the αβ T-cell repertoire: implications for disease pathogenesis and vaccination,” *Immunology and Cell Biology*, vol. 89, no. 3, pp. 375–387, 2011.

[29] N. J. Singh, J. K. Bando, and R. H. Schwartz, “Subsets of non-clonal neighboring CD4+ T cells specifically regulate the frequency of individual antigen-reactive T cells,” *Immunity*, vol. 37, no. 4, pp. 735–746, 2012.

[30] C.-F. Huang, S.-S. Lin, Y.-C. Ho, F.-L. Chen, and C.-C. Yang, “The immune response induced by hepatitis B virus principal antigens,” *Cellular & Molecular Immunology*, vol. 3, no. 2, pp. 97–106, 2006.

[31] X.-S. Yao, G.-W. Zhang, L. Ma et al., “Analysis of the CDR3 length of TCRαβ T cells in the peripheral blood of patients with chronic hepatitis B,” *Hepatology Research*, vol. 35, no. 1, pp. 10–18, 2006.

[32] C. P. Desmond, A. Bartholomeusz, S. Gaudieri, P. A. Revill, and S. R. Lewin, “A systematic review of T-cell epitopes in hepatitis B virus: identification, genotypic variation and relevance to antiviral therapeutics,” *Antiviral Therapy*, vol. 13, no. 2, pp. 161–173, 2008.

[33] M. G. Ghany and E. C. Doo, “Management of chronic hepatitis B,” *Gastroenterology Clinics of North America*, vol. 33, no. 3, pp. 563–579, 2004.

[34] R. A. Morgan, M. E. Dudley, J. R. Wunderlich et al., “Cancer regression in patients after transfer of genetically engineered lymphocytes,” *Science*, vol. 314, no. 5796, pp. 126–129, 2006.

[35] S.-A. Xue, L. Gao, S. Thomas et al., “Development of a Wilms’ tumor antigen-specific T-cell receptor for clinical trials: engineered patient’s T cells can eliminate autologous leukemia blasts in NOD/SCID mice,” *Haematologica*, vol. 95, no. 1, pp. 126–134, 2010.

[36] A. J. Gehring, S.-A. Xue, Z. Z. Ho et al., “Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines,” *Journal of Hepatology*, vol. 55, no. 1, pp. 103–110, 2011.

[37] S. Koh, N. Shimasaki, R. Suwanarusk et al., “A practical approach to immunotherapy of hepatocellular carcinoma using T cells redirected against hepatitis B virus,” *Molecular Therapy—Nucleic Acids*, vol. 2, article e114, 2013.

[38] K. Krebs, N. Böttiger, L.-R. Huang et al., “T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice,” *Gastroenterology*, vol. 145, no. 2, pp. 456–465, 2013.

[39] J. Wu, L. Wang, Y. Liu et al., “Transgenic expression of T cell receptors on HBV-specific cytotoxic T lymphocytes,” *Xi Bao Yu Fei Zi Mian Yi Xue Za Zhi*, vol. 29, no. 5, pp. 453–457, 2013.

[40] J. Yang, I. He, H. Lu et al., “Molecular features of the complementarity determining region 3 motif of the T cell population and subsets in the blood of patients with chronic severe hepatitis B,” *Journal of Translational Medicine*, vol. 9, no. 1, article 210, 2011.

[41] M. Rybicka, P. Stalke, M. Dreczewski, T. Smiatacz, and K. P. Bielawski, “High-throughput matrix-assisted laser desorption ionization-time of flight mass spectrometry as an alternative approach to monitoring drug resistance of hepatitis B virus,” *Journal of Clinical Microbiology*, vol. 52, no. 1, pp. 9–14, 2014.

[42] H. S. Robins, P. V. Camppregher, S. K. Srivastava et al., “Comprehensive assessment of T-cell receptor β-chain diversity in αβ T cells,” *Blood*, vol. 114, no. 19, pp. 4099–4107, 2009.

[43] Y. Han, X. Liu, Y. Wang et al., “Identification of characteristic TRB V usage in HBV-associated HCC by using differential expression profiling analysis,” *OncoImmunology*, vol. 4, no. 8, article e021537, 2015.

[44] Y. Huang, H. Ma, S. Wei et al., “Analysis of the complementarity determining regions β-chain genomic rearrangement using high-throughput sequencing in periphery cytotoxic T lymphocytes of patients with chronic hepatitis B,” *Molecular Medicine Reports*, vol. 14, no. 1, pp. 762–768, 2016.

[45] J. Yang, J. Chen, H. Mao et al., “Skewed T-cell receptor beta chain variable gene (TCRBV) usage among different clinical types of patients with chronic HBV infection,” *FEBS Immunology and Medical Microbiology*, vol. 65, no. 3, pp. 448–455, 2012.

[46] S.-W. Qiao, A. Christophersen, K. E. A. Lundin, and L. M. Sollid, “Biased usage and preferred pairing of α-and β-chains of TCRs specific for an immunodominant gluten epitope in coeliac disease,” *International Immunology*, vol. 26, no. 1, pp. 13–19, 2014.

[47] J. R. Oksenberg, S. Stuart, A. B. Begovich et al., “Limited heterogeneity of rearranged T-cell receptor V alpha transcripts in brains of multiple sclerosis patients,” *Nature*, vol. 353, no. 6339, article 94, 1991.

[48] M. Arenz, K.-H. Meyer Zum Büschenfelde, and H. F. Löhr, “Limited T cell receptor Vß-chain repertoire of liver-infiltrating T cells in autoimmune hepatitis,” *Journal of Hepatology*, vol. 28, no. 1, pp. 70–77, 1998.

[49] M. Arenz, S. Pingel, P. Schirmacher, K.-H. Meyer zum Büschenfelde, and H. F. Löhr, “T cell receptor Vß chain restriction and preferred CDR3 motifs of liver-kidney microsomal antigen (LKM-1)-reactive T cells from autoimmune hepatitis patients,” *Liver*, vol. 21, no. 1, pp. 18–25, 2001.

[50] Y. Hoshino, N. Enomoto, N. Izumi, M. Kuroasaki, F. Marumo, and C. Sato, “Limited usage of T-cell receptor β chains and sequences of the complementarity determining region 3 of lymphocytes infiltrating in the liver of autoimmune hepatitis,” *Hepatology*, vol. 22, no. 1, pp. 142–147, 1995.

[51] U. Moebius, M. Manns, G. Hess, G. Kober, K.-H. Meyer Zum Büschenfelde, and S. C. Meuer, “T cell receptor gene rearrangements of T lymphocytes infiltrating the liver in chronic active hepatitis B and primary biliary cirrhosis (PBC): oligoclonality of PBC-derived T cell clones,” *European Journal of Immunology*, vol. 20, no. 4, pp. 889–896, 1990.